Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib in Japanese Patients With Neuroendocrine Tumors
NCT05077384Phase 2Completed
- Sponsor
- HUTCHMED
- Start
- Sep 2021
- Primary completion
- Sep 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of surufatinib in neuroendocrine tumors (NETs), Nonhematologic neoplasms, sponsored by HUTCHMED. Started Sep 2021; status: completed.
02
Drugs
surufatinib
03
Conditions
neuroendocrine tumors (NETs)Nonhematologic neoplasms
Beyond the preview
Go deeper on NCT05077384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05077384.